TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial


John Nemunaitis, et al.
SITC 2015, November 2015 – Abstract available on the SITC website
Download the poster here
Poster Presentation

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00 - Fax. : + 33 (0) 3 88 27 91 11

 

© 2018 Transgene - All rights reserved
Mentions légales - Crédits